Long-Acting Injectable Antipsychotic Medication Plus Customized Adherence Enhancement in Poor Adherence Patients With Bipolar Disorder

Martha Sajatovic, Jennifer B. Levin, Luis F. Ramirez, Kristin A. Cassidy, Nora McNamara, Edna Fuentes‐Casiano, Betsy Wilson, Deionte Appling, Farren Briggs

The Primary Care Companion For CNS Disorders · 2021 · 12 citations · 0 references

Concepts

Abstract

People with bipolar disorder (BD) often have difficulty with medication adherence. This pilot trial combined a behavioral customized adherence enhancement (CAE) approach with long-acting injectable (LAI) antipsychotic medication and assessed effects on adherence, BD symptoms, and functional status. This 6-month prospective, uncontrolled trial of the intervention (CAE with LAI) in 30 poorly adherent individuals with BD assessed adherence using the Tablets Routine Questionnaire (TRQ) and symptoms using the Brief Psychiatric Rating Scale (BPRS), Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), and Clinical Global Impressions (CGI). Functioning was assessed via the Social and Occupational Functioning Assessment Scale (SOFAS) and Global Assessment of Functioning (GAF). Assessments were conducted at screening, baseline, week 12, and week 24 (6 months). The LAI was aripiprazole once monthly. The study was conducted between April 2018 and May 2020. < .001). A personalized intervention to address adherence barriers combined with LAI can improve recovery outcomes in high-risk individuals with BD. ClinicalTrials.gov Identifier: NCT03408873.